Cyclacel Pharmaceuticals market cap is $47.8 m.

Cyclacel Pharmaceuticals Net income (Q1, 2021)-3.5 M

Cyclacel Pharmaceuticals EBIT (Q1, 2021)-4.3 M

Cyclacel Pharmaceuticals Cash, 31-Mar-202147.8 M

Cyclacel Pharmaceuticals EV1.1 M

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 699.0k | 69.0k | 1.1m | 1.7m | 1.9m | 843.0k | 150.0k | |||

| 60% | 12% | (57%) | |||||||

## Cost of goods sold | 360.0k | |||||||||

## Gross profit | 339.0k | |||||||||

| 48% | |||||||||

## R&D expense | 9.2m | 6.6m | 11.3m | 18.3m | 12.4m | 9.5m | 4.2m | 4.3m | 4.7m | 4.8m |

## General and administrative expense | 7.5m | 8.6m | 7.8m | 5.9m | 5.7m | 5.5m | 5.3m | 5.4m | 5.0m | 5.9m |

## Operating expense total | 16.7m | 15.2m | 19.1m | 24.2m | 18.1m | 15.0m | 9.5m | 9.7m | 9.7m | 10.6m |

## EBIT | (16.4m) | (15.1m) | (18.0m) | (22.4m) | (16.2m) | (14.1m) | (9.5m) | (9.5m) | (9.7m) | (10.6m) |

| (2344%) | (21888%) | (1658%) | (1294%) | (832%) | (1679%) | (6365%) | |||

## Interest expense | 580.0k | 4.0k | 6.1m | 212.0k | 316.0k | 376.0k | 1.0m | 923.0k | ||

## Interest income | 45.0k | 22.0k | 13.0k | 6.0k | 9.0k | 37.0k | 118.0k | 331.0k | 224.0k | 42.0k |

## Pre tax profit | (15.8m) | (15.1m) | (11.9m) | (22.6m) | (16.5m) | (13.8m) | (8.5m) | (8.6m) | (9.1m) | (9.7m) |

## Income tax expense | (565.0k) | (1.4m) | (1.7m) | (3.2m) | (2.1m) | (2.0m) | (993.0k) | (1.3m) | (1.3m) | (1.2m) |

## Net Income | (15.2m) | (13.2m) | (10.2m) | (19.4m) | (14.3m) | (11.8m) | (7.5m) | (7.3m) | (7.8m) | (8.4m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Cash | 24.4m | 16.4m | 31.1m | 24.2m | 20.4m | 16.5m | 23.9m | 17.5m | 11.9m | 33.4m |

## Prepaid Expenses | 1.2m | 1.6m | 3.4m | 4.6m | 4.1m | 2.1m | 2.3m | 2.1m | 2.1m | |

## Inventories | 182.0k | |||||||||

## Current Assets | 25.8m | 18.9m | 35.2m | 29.0m | 24.6m | 19.6m | 26.0m | 19.8m | 14.0m | 35.5m |

## PP&E | 167.0k | 129.0k | 275.0k | 387.0k | 198.0k | 45.0k | 29.0k | 36.0k | 27.0k | 106.0k |

## Total Assets | 26.0m | 19.4m | 35.5m | 29.4m | 24.8m | 19.7m | 26.0m | 19.8m | 15.3m | 36.8m |

## Accounts Payable | 1.8m | 2.3m | 2.5m | 2.8m | 1.9m | 2.5m | 1.6m | 2.7m | 890.0k | 514.0k |

## Current Liabilities | 6.5m | 9.3m | 7.5m | 7.5m | 5.8m | 5.3m | 4.1m | 4.5m | 2.4m | 2.5m |

## Long-term debt | 1.2m | 1.1m | ||||||||

## Total Debt | 1.2m | 1.1m | ||||||||

## Total Liabilities | 6.5m | 9.3m | 7.5m | 7.7m | 5.9m | 5.4m | 4.2m | 4.6m | 3.6m | 3.5m |

## Common Stock | 54.0k | 9.0k | 19.0k | 23.0k | 35.0k | 12.0k | 12.0k | 17.0k | 6.0k | |

## Preferred Stock | 1.0k | 1.0k | ||||||||

## Additional Paid-in Capital | 276.5m | 280.2m | 317.5m | 331.0m | 342.6m | 350.1m | 365.1m | 365.8m | 370.1m | 400.1m |

## Retained Earnings | (257.1m) | (270.2m) | (289.4m) | (308.8m) | (323.2m) | (335.0m) | (342.5m) | (349.8m) | (357.6m) | (366.1m) |

## Total Equity | 19.5m | 10.0m | 28.0m | 21.7m | 18.8m | 14.3m | 21.8m | 15.3m | 11.7m | 33.3m |

## Financial Leverage | 1.3 x | 1.9 x | 1.3 x | 1.4 x | 1.3 x | 1.4 x | 1.2 x | 1.3 x | 1.3 x | 1.1 x |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (15.2m) | (13.2m) | (10.2m) | (19.4m) | (14.3m) | (11.8m) | (7.5m) | (7.3m) | (7.8m) | (8.4m) |

## Depreciation and Amortization | 241.0k | 60.0k | 70.0k | 174.0k | 210.0k | 133.0k | 32.0k | 29.0k | 20.0k | 20.0k |

## Accounts Payable | 577.0k | 1.8m | (750.0k) | 666.0k | (1.5m) | 370.0k | (1.5m) | 554.0k | (2.2m) | 30.0k |

## Cash From Operating Activities | (14.0m) | (12.0m) | (18.2m) | (18.7m) | (14.5m) | (10.1m) | (7.5m) | (6.7m) | (9.4m) | (7.9m) |

## Purchases of PP&E | (6.0k) | (12.0k) | (208.0k) | (309.0k) | (34.0k) | (3.0k) | (13.0k) | (39.0k) | (10.0k) | (96.0k) |

## Cash From Investing Activities | (1.0k) | 50.0k | 5.7m | 75.0k | 62.0k | 9.0k | (13.0k) | (39.0k) | 28.0k | (96.0k) |

## Dividends Paid | (364.0k) | (305.0k) | (200.0k) | (201.0k) | (200.0k) | (201.0k) | (201.0k) | (201.0k) | (201.0k) | |

## Cash From Financing Activities | 8.9m | 4.0m | 27.3m | 12.2m | 10.9m | 6.6m | 14.7m | 429.0k | 3.8m | 29.5m |

## Net Change in Cash | (5.0m) | (8.0m) | 14.7m | (7.0m) | (3.7m) | (3.9m) | 7.4m | (6.4m) | (5.6m) | 21.5m |

## Interest Paid | 331.0k | |||||||||

## Income Taxes Paid | (1.0m) | 1.8m | 1.2m |

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.4 x |